H
Haolan Lu
Researcher at Bristol-Myers Squibb
Publications - 11
Citations - 1663
Haolan Lu is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Cetuximab & Ipilimumab. The author has an hindex of 8, co-authored 11 publications receiving 1505 citations.
Papers
More filters
Journal ArticleDOI
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Titus Chacko,Martin Sebastian,Joel W. Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck +10 more
TL;DR: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipil optimumab in NSCLC.
Journal ArticleDOI
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
Martin Reck,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Titus Chacko,Martin Sebastian,Haolan Lu,J.-M. Cuillerot,Thomas J. Lynch +9 more
TL;DR: The results of this phase 2 study suggest further investigation of ipilimumab in ED-SCLC, and highlight the need for further investigation into the anti-CTLA4 monoclonal antibody.
Journal ArticleDOI
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Suresh Ramalingam,Judy Forster,C. L. Naret,Terry Evans,Matt Sulecki,Haolan Lu,Paola Teegarden,Martin R. Weber,Chandra P. Belani +8 more
TL;DR: Dual EGFR inhibition with cetuximab and gefitinib is feasible; the combination can be safely administered and may have modest activity in advanced/metastatic NSCLC.
Journal ArticleDOI
Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium
Tanya M. Trippett,Cynthia E. Herzog,James A. Whitlock,Johannes E. A. Wolff,John F. Kuttesch,Rochelle Bagatell,Stephen P. Hunger,Jessica Boklan,Amy Smith,Robert J. Arceci,Howard M. Katzenstein,Christopher T. Harbison,Xiaofei Zhou,Haolan Lu,Christiane Langer,Martin R. Weber,Lia Gore +16 more
TL;DR: The cetuximab/irinotecan combination can be given safely to children and adolescents with cancer, and promising activity, particularly in CNS tumors, warrants phase II evaluation of this regimen.
Journal ArticleDOI
OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
Solange Peters,Frederico Cappuzzo,Leora Horn,Luis Paz-Ares,Hossein Borghaei,Fabrice Barlesi,Martin Steins,Enriqueta Felip,David R. Spigel,Cecile Dorange,Haolan Lu,Diane Healey,Teresa Sanchez,Prabhu Bhagavatheeswaran,James Novotny,Brian Lestini,Julie R. Brahmer +16 more